<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): JUNE 9, 2000
--------------------------
TRANSKARYOTIC THERAPIES, INC.
----------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE
-----------------------------------------------------
(State or Other Jurisdiction of Incorporation)
000-21481 04-3027191
----------------------- ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
195 ALBANY STREET, CAMBRIDGE, MASSACHUSETTS 02139
----------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617)349-0200
---------------------------------------------------------------------
Registrant's Telephone Number, Including Area Code
NOT APPLICABLE
---------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
Item 5. OTHER EVENTS.
---------------
On June 9, 2000, Transkaryotic Therapies, Inc. (the "Registrant")
sold 9,000 shares of the Registrant's Series A Convertible Preferred Stock,
$0.01 par value per share, for an aggregate price of $90,000,000 to
investment funds affiliated with E.M. Warburg, Pincus & Co., L.L.C.
(collectively, "Warburg Pincus") pursuant to a Stock Purchase Agreement,
dated as of May 18, 2000 (the "Purchase Agreement"), Under the terms of the
Purchase Agreement, the 9,000 shares of Series A Convertible Preferred Stock
shall convert into approximately 3,213,000 shares of the Registrant's common
stock, $0.01 par value per share, at a conversion price of $28.00 per share.
2
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 9, 2000
TRANSKARYOTIC THERAPIES, INC.
(Registrant)
BY: /s/ Daniel E. Geffken
------------------------------
Daniel E. Geffken
Vice President, Finance and
Chief Financial Officer
3
